Growth hormone therapy in heart failure: Where are we now?

Congestive Heart Failure

Volumn 9, Issue 2, 2003, Pages 84-90

  Demers, Catherine ^b   McKelvie, Robert S ^a  

^a HHS General Hospital   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; HUMAN GROWTH HORMONE; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADJUVANT THERAPY; APOPTOSIS; CACHEXIA; CELL GROWTH; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; GENE INDUCTION; GROWTH HORMONE BLOOD LEVEL; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART PACING; HEART STROKE VOLUME; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HORMONAL THERAPY; HUMAN; HYPERTENSION; INOTROPISM; MORBIDITY; MORTALITY; ONCOGENE C MYC; PROGNOSIS; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SARCOPLASMIC RETICULUM; SWINE; THORAX PAIN; VASCULAR RESISTANCE; VASODILATATION;

EID: 0345700684     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2003.00283.x     Document Type: Review

References (52)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
2. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991; 325:303-310.
3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
4. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
5. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 1999;353:9-13.
6. Packer M, Bristow M, Cohn J, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
7. Ross J Jr, Hongo M. The role of hypertrophy and growth factors in heart failure. J Card Fail. 1997;2:S121.
8. Ross J Jr, Ryoke T. Effects of growth hormone and insulin-like growth factor I in experimental heart failure. Growth Horm IGF Res. 1998;8:159-161.
9. Isgaard J, Tivesten A, Friberg P, et al. The Role of GH/IGF-I axis for cardiac function and structure. Horm Metab Res. 1999; 31:50-54.
10. Volterrani M, Manelli F, Cicoira M, et al. Role of growth hormone in chronic heart failure. Drugs. 2000;60:711-719.
11. Isgaard J, Nilsson A, Vikman K, et al. Growth hormone regulates the level of insulin-like growth factor I in rat skeletal muscle. J Endocrinol. 1989;120:107-112.
12. Mathews LS, Enberg B, Norstedt G. Regulation of rat growth hormone receptor gene expression. J Biol Chem. 1989;17: 9905-9910.
13. Saccà L. Growth hormone therapy for heart failure: swimming against the stream. J Card Fail. 1999;5:269-275.
14. Ito H, Hiroe M, Hirata Y, et al. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation. 1993;87:1715-1721.
15. Mayoux E, Ventura-Clapier R, Timsit J, et al. Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ Res. 1993;72:57-64.
16. Tajima M, Weinberg EO, Bartunek J, et al. Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation. 1999;99:127-134.
17. Cuneo RC. GH and cardiac failure [editorial]. J. Clin Endocrinol Metab. 2001;86:4638-4643.
18. Fazio S, Cittadini A, Biondi B, et al. Growth hormone as a potential future therapy for congestive heart failure. Coron Artery Dis. 1999;10:383-388.
19. deBoer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995;16: 63-86.
20. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone deficient adults. I. Effects on muscle mass and strength. J Appl Physiol. 1991;70:688-694.
21. Cuneo RC, Salomon F, Wiles CM, et al. Growth hormone treatment in growth hormone-deficient adults. II. Effects on exercise performance. J Appl Physiol. 1991;70:695-700.
22. Frustaci A, Perrone GA, Gentolini N, et al. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol. 1992;97:503-511.
23. Cuneo RC, Wilmshurst P, Lowy C, et al. Cardiac failure responding to growth hormone. Lancet. 1989;1(8642):838-839.
24. Whitehead HM, Boreham C, McIlrath EM, et al. Growth hormone treatment of adults with growth hormone deficiency: results of a 13-month placebo controlled crossover study. Clin Endocrinol. 1992;36:45-52.
25. Frustaci A, Gentiloni N, Russo MA. Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996; 335:672-673.
26. Yang R, Bunting S, Gillett N, et al. Growth hormone improves cardiac performance in experimental heart failure. Circulation. 1995;92:262-267.
27. Duerr RL, Huang S, Miraliakbar HR, et al. Insulin-like growth factor-I enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest. 1995;95:619-627.
28. Ambler GR, Johnston BM, Maxwell L, et al. Improvement of doxorubicin-induced cardiomyopathy in rats treated with insulin-like growth factor-I. J Cardiovasc Res. 1993;27: 1369-1373.
29. Duerr RL, McKirnan MD, Gim RD, et al. Cardiovascular effects of insulin-like growth factor-I and growth hormone in chronic left ventricular failure in the rat. Circulation. 1996;93: 2188-2196.
30. Jin H, Yang R, Gillett N, et al. Beneficial effects of growth hormone and insulin-like growth factor-I in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharmacol. 1995;26:420-425.
31. Shen YT, Wiedmann RT, Lynch JJ, et al. Growth hormone replacement fails to improve ventricular function in hypophysectomized rats with myocardial infarction. Am J Physiol. 1996;271:H1721-H1726.
32. Shen YT, Woltmann RF, Appleby S, et al. Lack of beneficial effects of growth hormone treatment in conscious clogs during development of heart failure. Am J Physiol. 1998;274: H456-H466.
33. Cittadini A, Grossman JD, Napoli R, et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol. 1997;29:1109-1116.
34. Buerke M, Murohara T, Skurk C, et al. Cardioprotective effect of insulin-like growth factor-I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A. 1995;92: 8031-8035.
35. Spinale FG, Houck WV, Pan LC. Growth hormone supplementation with developing congestive heart failure: effects on left ventricular cellular structure and composition [abstract]. Circulation. 1998;98:I180.
36. Timsit J, Riou B, Bertherat J, et al. Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphate activity of the rat left ventricle. J Clin Invest. 1990;86:507-515.
37. King MK, Gay DM, Pan LC, et al. Treatment with a growth hormone secretagogue in a model of developing heart failure. Effects on ventricular and myocyte function. Circulation. 2001;103:308-313.
38. Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;334:809-814.
39. O'Driscoll JG, Green DJ, Ireland M, et al. Treatment of end-stage cardiac failure with growth hormone. Lancet. 1997;349: 1068.
40. Roman DL, Bobillo ER. Reversing idiopathic dilated cardiomyopathy with growth hormone: is this possible? Ann Intern Med. 1997;126:834.
41. Genth-Zotz S, Zotz R, Geil S, et al. Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity. Circulation. 1999; 99:18-21.
42. Volterrani M, Desenzani P, Lorusso R, et al. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet. 1997;349:1067-1068.
43. Jose J, Zechariah TU, George P. Growth hormone therapy in patients with dilated cardiomyopathy: preliminary observations of a pilot study. Indian Heart J. 1999;51:183-185.
44. Spallarossa P, Rossettin P, Minuto F, et al. Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease. Am J Cardiol. 1999;84:430-433.
45. Giustina A, Volterrani M, Manelli F, et al. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. Am Heart J. 1999;137:1035-1043.
46. Capaldo B, Lembo G, Rendina V, et al. Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy. Eur Heart J. 1998;19:623-627.
47. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233-1237.
48. Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J. 1998;19:1704-1711.
49. Smit JWA, Janssen YJH, Lamb HJ, et al. Six months of recombinant human GH therapy in patients with ischemic cardiac failure does not influence left ventricular function and mass. J Clin Endocrinol Metab. 2001;86:4638-4643.
50. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes in catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96: 526-534.
51. Anker SD, Volterrani M, Pflaum CD, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol. 2001;38:443-452.
52. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785-792.